[8-K] OS Therapies Incorporated Reports Material Event

Rhea-AI Filing Summary

OS Therapies Incorporated filed a Form 8-K disclosing a material event via a press release issued on August 19, 2025. The filing identifies the company’s common stock as having a par value of $0.001 per share and trading under the ticker OSTX on the NYSE American. The document is signed by Paul A. Romness, MPH, President and Chief Executive Officer.

The submission includes the cover page interactive data reference and checkboxes for Rule 425 and soliciting/pre-commencement communications, though none of those boxes are marked. The filing therefore publicly documents that a press release was issued and that the company formally reported a material event to the market on the date shown.

Positive

• Form 8-K filed documenting a press release dated August 19, 2025
• CEO-signed disclosure (Paul A. Romness, MPH) confirming authorization

Negative

• None.

Insights

Corporate Filings Analyst

Filing confirms a material-event press release was officially reported.

The Form 8-K records that OS Therapies distributed a press release on August 19, 2025 and filed the disclosure with the SEC, which is the standard mechanism for public companies to notify investors of material events.

This filing contains corporate identifiers—OSTX, NYSE American, and $0.001 par value—and a CEO signature, establishing the filing's formality and authorization.

Investor Relations Specialist

The company publicly posted a material-event press release and documented it via 8-K signature.

Registering the press release on Form 8-K ensures the market receives a formal disclosure dated August 19, 2025. The filing references interactive data but does not mark the Rule 425 or soliciting/pre-commencement checkboxes.

Because the 8-K points to a press release rather than including substantive text here, investors should refer to the press release itself for details of the material event.

false 0001795091 0001795091 2025-08-19 2025-08-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 19, 2025

OS THERAPIES INCORPORATED

(Exact name of registrant as specified in its charter)

Delaware		001-42195		82-5118368
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

115 Pullman Crossing Road, Suite 103 Grasonville, Maryland		21638
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (410) 297-7793

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share		OSTX		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

CURRENT REPORT ON FORM 8-K

OS Therapies Incorporated

August 19, 2025

Item 2.02. Results of Operations and Financial Condition.

On August 19, 2025, OS Therapies Incorporated, a clinical-stage cancer immunotherapy and ADC biotechnology company, issued a press release announcing its financial results for the quarter ended June 30, 2025 and providing a business update.

A copy of the press release is furnished with this report as Exhibit 99.1. Such information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press Release issued by OS Therapies Incorporated on August 19, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	OS THERAPIES INCORPORATED
Dated: August 19, 2025	By:	/s/ Paul A. Romness, MPH
		Name:	Paul A. Romness, MPH
		Title:	President and Chief Executive Officer

2

FAQ

What did OS Therapies (OSTX) file on August 19, 2025?

OS Therapies filed a Form 8-K disclosing a material event and noting a press release issued on August 19, 2025.

Where does OSTX trade and what is the par value of its common stock?

OSTX trades on the NYSE American and its common stock has a par value of $0.001 per share.

Who signed the 8-K for OS Therapies?

The Form 8-K is signed by Paul A. Romness, MPH, President and Chief Executive Officer.

Does the filing indicate use of Rule 425 or soliciting/pre-commencement communications?

The filing shows the checkboxes for Rule 425 and soliciting/pre-commencement communications, but none of those boxes are marked in the provided content.

Does the 8-K include the press release text or detailed event information?

The provided filing references a press release but the substantive press release text is not included in the content presented here.